Compare Novo Nordisk A/S (NVO) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Energy Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $46.17 (market cap $207.85B), while Energy Select Sector SPDR Fund trades at $60.99. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Energy Select Sector SPDR Fund pays none, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | XLE | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | — |
52-Week High | $63.98 | $62.57 |
52-Week Low | $35.29 | $42.33 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
XLE trades at $60.87, up 1.13% with strong technical momentum as moving averages signal bullish conditions. The energy ETF has rallied approximately 40% over the past year, driven by elevated oil prices and geopolitical tensions in the Middle East. Recent earnings from major holdings like ExxonMobil and Chevron show strong profit growth, though valuation metrics remain undisclosed in current data.
Outlook remains positive with energy sector leadership in 2026 performance, though geopolitical risks and high volatility present challenges. The ETF's low 0.08% expense ratio and concentrated exposure to oil giants offer efficient energy market access, but dependence on Middle East stability creates significant price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
